



Collaborative Research Network

Dare to Dream of a Future without Lows

Julie Raskin 2023 CHI Family Conference April 14-16, 2023 Children's Hospital of Philadelphia



CHI CRN Mission and Cornerstones

Create a congenital hyperinsulinism (HI) collaborative research network (CRN) that puts patients at the center of a strategy that leads to faster and more accurate diagnosis, drives new evidencebased treatments and cures, standardizes clinical guidelines, and facilitates increased and improved access.

The HI CRN has a commitment to:

- supporting collaboration across the globe;
- elevating the patient voice and ensuring the patient perspective is central to our work;
- guaranteeing access to information, medical specialists, and treatments regardless of income and geography;
- engaging new researchers and ideas to find innovative concepts and foster additional leaders in the HI network; and
- addressing diversity, equity, and inclusion in our work and our community.



Dare to Dream of a Future without Lows









Workstreams

Themes

- What is HI?: Nomenclature and Inclusion
- Medical and surgical treatments
- Care Guidelines/centers of excellence
- Diagnostics
- Glucose monitoring
- Clinical trials/industry engagement
- Genetics

Activities and Deliverables

- Clearly defined workstream topics
- Brainstorm to generate a gap analysis document
- Identify the gaps in:
 - Research gaps or needs
 - Infrastructure/ Pooled Research Resources/ Collaboration
 - Knowledge/ Expertise
 - Dissemination/ Funding
- Describe the elements needed to fill the gaps
- Prioritize the elements and create a workplan



Workflow



Phase 1: 2020- May 2022

Phase 2: June 2022-

CHI CRN Convening Lisbon, Portugal May 20-22, 2022

Meeting goals:

- (1) Finalize the first CHI prioritized research agenda;
- (2) Adopt a CRN membership structure and decide on communication strategies/ future meetings; and
- (3) Begin discussion of concrete collaborative research projects.



Top 12 Gaps/Needs Prioritized at Lisbon CRN Convening

| Workstream | Gap/Need |
|---|---|
| All | HI Natural History Study |
| Diagnostics | Identification and adoption of newborn screening approach |
| Diagnostics | Glucose as a vital sign |
| Medical and Surgical Treatments | Knowledge of the cause of neurological damage |
| Care Guidelines & Centers of Excellence | Continually evolving global care guidelines |
| Clinical Trials & Industry Engagement | An expert group to develop novel clinical trials and outcome measures for regulatory approval |
| Genetics | Access to genetic testing |
| Diagnostics | A biomarker for hyperinsulinism |
| Clinical Trials & Industry Engagement | Meaningful glycemic endpoints |
| Glucose Monitoring | Device technology for HI patients |
| Medical and Surgical Treatments | Implementation of personalized medicine |
| Clinical Trials & Industry Engagement | Expand access and accelerate enrollment in clinical trials |

Concrete Project Actions: Lisbon CHI CRN Convening

All projects will be mapped to the patient journey and will be led by goals and cornerstones

Identification and adoption of newborn screening approach/ Glucose as a vital sign

- Marketing campaign
- Newborn glucose and ketone pilot studies

•

Knowledge of the cause of neurological damage

- Multi-center prospective cohort study utilizing CGMs and standardized outcome measures
- Basic science / lab studies for specific gene mutations and understanding mechanisms

Continually evolving global care guidelines

- Caregiver care guidelines
- Guidelines adapted for different languages/ cultures that reflect resource restraints
- Incorporation of the patient voice

An expert group to develop novel clinical trials and outcome measures for regulatory approval

- Assemble outside expertise
- PFDD FDA meeting
- Establish a workgroup and committee



Progress Since Lisbon

Explosion of Research



